(NASDAQ: MTVA) Metavia's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.6%.
Metavia's earnings in 2025 is -$27,592,000.On average, 3 Wall Street analysts forecast MTVA's earnings for 2025 to be -$16,876,995, with the lowest MTVA earnings forecast at -$22,935,403, and the highest MTVA earnings forecast at -$8,135,577. On average, 2 Wall Street analysts forecast MTVA's earnings for 2026 to be -$21,204,429, with the lowest MTVA earnings forecast at -$28,128,324, and the highest MTVA earnings forecast at -$14,280,534.
In 2027, MTVA is forecast to generate -$28,690,891 in earnings, with the lowest earnings forecast at -$44,139,832 and the highest earnings forecast at -$13,241,950.